Primary Care Clinics in Robbinsdale, MN Accepting Medicare
6 Primary Care Clinics found. Showing 1 - 6
 North Memorial Health Trauma Clinic/Center - Multi-Specialty Medicare: Not Enrolled in Medicare Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-581-4674 Fax: 763-581-4561 |
Mark P Stesin Md Pa Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 3366 Oakdale Ave N, Suite 408, Robbinsdale, MN 55422 Phone: 763-520-5876 Fax: 763-520-1703 |
Robbinsdale Clinic, P.a. Family Medicine Medicare: Medicare Enrolled Practice Location: 3819 W Broadway Ave, Robbinsdale, MN 55422 Phone: 763-533-2534 |
Medical Consultants Clinic Pa Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 4600 Lake Road Ave Ste 301, Robbinsdale, MN 55422 Phone: 763-588-7099 Fax: 763-522-2222 |
Concentra Urgent Care Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 4080 W Broadway Ave Ste 200, Robbinsdale, MN 55422 Phone: 763-398-8888 Fax: 763-398-0670 |
Oakdale Family Practice, Pc Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 3366 Oakdale Ave N, Suite 403, Robbinsdale, MN 55422 Phone: 763-529-9131 Fax: 763-529-5519 |
News Archive
Herpes zoster vaccine reduces risk of developing shingles by 55%
Receiving the herpes zoster vaccine was associated with a 55 percent reduced risk of developing shingles, according to a Kaiser Permanente study of 300,000 people that appears in the current issue of the Journal of the American Medical Association.
Takeda Rika Kogyo to distribute WaferGen's SmartChip Real-Time PCR System in Japan
WaferGen Biosystems, Inc., a leading developer of state-of-the-art genome analysis systems, today announced the signing of an exclusive distribution agreement for the company's SmartChip Real-Time PCR System with Takeda Rika Kogyo Co., Ltd., a leading distributor of innovative products and services in the life science markets within Japan.
SCYNEXIS receives four grants under QTDP program to develop cyclophilin inhibitors
Drug discovery and development company SCYNEXIS, Inc. today announced that the Company has been awarded four grants totaling $977,917 under the U.S. Federal Government's Qualifying Therapeutic Discovery Project (QTDP). SCYNEXIS is developing a proprietary internal pipeline of cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases.
Researchers induce cell death in leukemia
Researchers from the Virginia Commonwealth University Massey Cancer Center presented preclinical research at the American Association of Cancer Research's annual meeting suggesting the potential of a new combination treatment for chronic lymphocytic leukemia (CLL).
Teen's radiation overdose down to paperwork
A report into the death of a teenage cancer patient who was given, in error, massive overdoses of radiation to treat a brain tumour, was apparently down to paperwork.
› Verified 8 days ago